An ongoing open-label, phase 2 trial of RP2 Or RP3 oncolytic immunotherapy in combination with atezolizumab and bevacizumab for the treatment of patients with advanced colorectal carcinoma

被引：0
|
作者：
Elez, E. [1 ,2 ]
Shepard, D. [3 ]
Smolenschi, C. [4 ]
Bekaii-Saab, T. [5 ]
Jac, J. [6 ]
机构：
[1] Vall dHebron Univ Hosp, Barcelona, Spain
[2] Vall dHebron Inst Oncol, Barcelona, Spain
[3] Cleveland Clin, Cleveland, OH 44106 USA
[4] Gustave Roussy, Dept Med Oncol, Villejuif, France
[5] Mayo Clin, Phoenix, AZ USA
[6] Replimune Inc, Woburn, MA USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.04.114
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-58
引用
收藏
页码：S34 / S35
页数：2
相关论文
共 50 条
  • [31] A randomized phase II (RP2) trial of ridaforolimus (R) compared with progestin (P) or chemotheraphy (C) in female adult patients with advanced endometrial carcinoma.
    Oza, A. M.
    Poveda, A.
    Clamp, A. R.
    Pignata, S.
    Scambia, G.
    Del Campo, J. M.
    McCormack, M.
    Sevcik, L.
    Schwartz, B. M.
    Guan, S.
    Lee, R.
    Cheng, J. D.
    Haluska, F. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [32] Initial Results from an Open-Label, Multicenter, Phase 1b/2 Study of RP1 Oncolytic Immunotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Advanced Cutaneous Malignancies (ARTACUS)
    Migden, M. R.
    Chai-Ho, W.
    Daniels, G. A.
    Davar, D.
    Wise-Draper, T.
    Kheterpal, M.
    Tang, J. C.
    Bolotin, D.
    Verschraegen, C.
    Poklepovic, A.
    Tsai, K. K.
    Navia, S.
    Hou, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2023, 23 (06) : S1200 - S1200
  • [33] An open-label, multicenter, phase I/II clinical trial of RP1 as a single agent and in combination with nivolumab in patients with solid tumors [IGNYTE]
    Aroldi, F.
    Middleton, M. R.
    Sacco, J. J.
    Milhem, M. M.
    Curti, B. D.
    VanderWalde, A. M.
    Baum, S. L.
    Samson, A.
    Chesney, J.
    Niu, J.
    Rhodes, T. D.
    Bowles, T. L.
    Olsson-Brown, A.
    Laux, D. E.
    Bommareddy, P. K.
    Menezes, L.
    Samakoglu, S.
    Pirzkall, A.
    Coffin, R. S.
    Harrington, K. J.
    ANNALS OF ONCOLOGY, 2021, 32 : S903 - S904
  • [34] Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312) : a multicentre, open-label, randomised, phase 3 trial
    Kelley, Robin Kate
    Rimassa, Lorenza
    Cheng, Ann-Lii
    Kaseb, Ahmed
    Qin, Shukui
    Zhu, Andrew X.
    Chan, Stephen L.
    Melkadze, Tamar
    Sukeepaisarnjaroen, Wattana
    Breder, Valery
    Verset, Gontran
    Gane, Edward
    Borbath, Ivan
    Rangel, Jose David Gomez
    Ryoo, Baek-Yeol
    Makharadze, Tamta
    Merle, Philippe
    Benzaghou, Fawzi
    Banerjee, Kamalika
    Hazra, Saswati
    Fawcett, Jonathan
    Yau, Thomas
    LANCET ONCOLOGY, 2022, 23 (08): : 995 - 1008
  • [35] Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial
    Galle, Peter R.
    Finn, Richard S.
    Qin, Shukui
    Ikeda, Masafumi
    Zhu, Andrew X.
    Kim, Tae-You
    Kudo, Masatoshi
    Breder, Valeriy
    Merle, Philippe
    Kaseb, Ahmed
    Li, Daneng
    Mulla, Sohail
    Verret, Wendy
    Xu, Derek-Zhen
    Hernandez, Sairy
    Ding, Beiying
    Liu, Juan
    Huang, Chen
    Lim, Ho Yeong
    Cheng, Ann-Lii
    Ducreux, Michel
    LANCET ONCOLOGY, 2021, 22 (07): : 991 - 1001
  • [36] AN OPEN-LABEL, MULTICENTER, PHASE 1/2 CLINICAL TRIAL OF RP1, AN ENHANCED POTENCY ONCOLYTIC HSV, COMBINED WITH NIVOLUMAB: UPDATED RESULTS FROM THE SKIN CANCER COHORTS
    Middleton, Mark
    Aroldi, Francesca
    Sacco, Joseph
    Milhem, Mohammed
    Curti, Brendan
    VanderWalde, Ari
    Baum, Scott
    Samson, Adel
    Pavlick, Anna
    Chesney, Jason
    Niu, Jiaxin
    Rhodes, Terence
    Bowles, Tawnya
    Conry, Robert
    Olsson-Brown, Anna
    Laux, Douglas Earl
    Kaufman, Howard
    Bommareddy, Praveen
    Deterding, Alex
    Samakoglu, Selda
    Coffin, Robert
    Harrington, Kevin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A257 - A257
  • [37] Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial
    Kudo, Toshihiro
    Hamamoto, Yasuo
    Kato, Ken
    Ura, Takashi
    Kojima, Takashi
    Tsushima, Takahiro
    Hironaka, Shuichi
    Hara, Hiroki
    Satoh, Taroh
    Iwasa, Satoru
    Muro, Kei
    Yasui, Hirofumi
    Minashi, Keiko
    Yamaguchi, Kensei
    Ohtsu, Atsushi
    Doki, Yuichiro
    Kitagawa, Yuko
    LANCET ONCOLOGY, 2017, 18 (05): : 631 - 639
  • [38] Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial
    Thomas, Anish
    Rajan, Arun
    Berman, Arlene
    Tomita, Yusuke
    Brzezniak, Christina
    Lee, Min-Jung
    Lee, Sunmin
    Ling, Alexander
    Spittler, Aaron J.
    Carter, Corey A.
    Guha, Udayan
    Wang, Yisong
    Szabo, Eva
    Meltzer, Paul
    Steinberg, Seth M.
    Trepel, Jane B.
    Loehrer, Patrick J.
    Giaccone, Giuseppe
    LANCET ONCOLOGY, 2015, 16 (02): : 177 - 186
  • [39] A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial
    Pal, Sumanta K.
    Tangen, Catherine
    Thompson, Ian M., Jr.
    Balzer-Haas, Naomi
    George, Daniel J.
    Heng, Daniel Y. C.
    Shuch, Brian
    Stein, Mark
    Tretiakova, Maria
    Humphrey, Peter
    Adeniran, Adebowale
    Narayan, Vivek
    Bjarnason, Georg A.
    Vaishampayan, Ulka
    Alva, Ajjai
    Zhang, Tian
    Cole, Scott
    Plets, Melissa
    Wright, John
    Lara, Primo N., Jr.
    LANCET, 2021, 397 (10275): : 695 - 703
  • [40] Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
    Rini, Brian I.
    Powles, Thomas
    Atkins, Michael B.
    Escudier, Bernard
    McDermott, David F.
    Suarez, Cristina
    Bracarda, Sergio
    Stadler, Walter M.
    Donskov, Frede
    Lee, Jae Lyun
    Hawkins, Robert
    Ravaud, Alain
    Alekseev, Boris
    Staehler, Michael
    Uemura, Motohide
    De Giorgi, Ugo
    Mellado, Begona
    Porta, Camillo
    Melichar, Bohuslav
    Gurney, Howard
    Bedke, Jens
    Choueiri, Toni K.
    Parnis, Francis
    Khaznadar, Tarik
    Thobhani, Alpa
    Li, Shi
    Piault-Louis, Elisabeth
    Frantz, Gretchen
    Huseni, Mahrukh
    Schiff, Christina
    Green, Marjorie C.
    Motzer, Robert J.
    LANCET, 2019, 393 (10189): : 2404 - 2415
12345